We provide you with 20 years of free, institutional-grade data for KROS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KROS. Explore the full financial landscape of KROS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Seehra Jasbir | Grant, award...etc | 90,500 | 2025-09-05 | ||
| Lerner Lorena Raquel | Initial | 2025-08-15 | |||
| Cho Esther | Initial | 2025-08-15 | |||
| Nussbaum Ran | Grant, award...etc | 5,250 | 2025-06-06 | ||
| Seth Alpna | Grant, award...etc | 5,250 | 2025-06-06 | ||
| GRAY MARY ANN | Grant, award...etc | 5,250 | 2025-06-06 | ||
| BIENAIME JEAN JACQUES | Grant, award...etc | 5,250 | 2025-06-06 | ||
| Farzan Nima | Grant, award...etc | 5,250 | 2025-06-06 | ||
| Kariv Tomer | Grant, award...etc | 5,250 | 2025-06-06 | ||
| Knowles Julius | Grant, award...etc | 5,250 | 2025-06-06 | ||
| GORDON CARL L | Grant, award...etc | 5,250 | 2025-06-06 | ||
| ADAR1 Capital Management, LLC | Open Market Purchase | 934,258 | $9.4 | 2025-04-11 | |
| Seehra Jasbir | Derivatives Exercise | 49,367 | 2025-04-07 | ||
| CHYUNG YUNG H. | Grant, award...etc | 44,000 | 2025-02-19 | ||
| Rovaldi Christopher | Grant, award...etc | 60,000 | 2025-02-19 | ||
| Regnante Keith | Grant, award...etc | 44,000 | 2025-02-19 | ||
| Regnante Keith | Sale | -40,000 | $45.29 | $1,811,600 | 2025-01-24 |
| Regnante Keith | Derivatives Exercise | 40,000 | 2025-01-24 | ||
| ORBIMED ADVISORS LLC | Sale | -29,400 | $44.01 | $1,293,894 | 2024-08-15 |
| ORBIMED ADVISORS LLC | Sale | -220,600 | $44.01 | $9,708,606 | 2024-08-15 |
| GORDON CARL L | Sale | -29,400 | $44.01 | $1,293,894 | 2024-08-15 |
| GORDON CARL L | Sale | -220,600 | $44.01 | $9,708,606 | 2024-08-15 |
| BIENAIME JEAN JACQUES | Initial | 2024-06-05 | |||
| Regnante Keith | Sale | -40,000 | $45.29 | $1,811,600 | 2024-01-08 |
| Regnante Keith | Derivatives Exercise | 40,000 | 2024-01-08 | ||
| Regnante Keith | Sale | -40,000 | $47.66 | $1,906,400 | 2023-06-12 |
| Regnante Keith | Derivatives Exercise | 40,000 | 2023-06-12 | ||
| Seehra Jasbir | Derivatives Exercise | 4,000 | 2023-04-11 | ||
| Knowles Julius | Open Market Purchase | 1,191 | $20.98 | 2023-01-20 |
The information provided in this report about KROS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Keros Therapeutics, Inc(NASDAQ:KROS) 
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, wh...
Website: http://www.kerostx.com
Founded: 2015
Full Time Employees: 32
CEO: Jasbir S. Seehra
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends